MICHEL P Coleman, Professor of Epidemiology and Vital Statistics, London School of Hygiene & Tropical Medicine, UK

Millions of cancer patients will continue to be diagnosed each year for the foreseeable future. They all need to access optimal health care. Population-based cancer survival is a key measure of the overall effectiveness of health systems in managing cancer. Survival varies very widely around the world. Global surveillance of cancer survival is required, because unless these largely avoidable inequalities are measured, and reported regularly, nothing will be done to ameliorate them.

PDF of article here

The burden of cancer In 2008, an estimated 12.7 million patients were diagnosed with cancer, and 7.6 million cancer deaths occurred. More than half (56%) of the cancer diagnoses and 64% of the deaths were among people living in low- and middle-income countries (LMIC)1. The annual number of newly diagnosed cancer patients will rise substantially by 2030 because of ageing of the world’s population, growth in population size and for many persons, an increase in their risk of developing cancer at each age (age-specific risks). All three factors will affect poorer countries more. Prevention remains preferable to cure, especially for such a lethal constellation of diseases. The need for long-term investment in primary prevention to reduce age-specific cancer risks for future populations remains equally inescapable. However, since we cannot expect the manufacturers and purveyors of tobacco to fall on their swords any time soon, the responsibility for primary prevention falls to politicians and other leaders of society with the courage, the selflessness and the long-term vision to develop and implement policies for cancer prevention that will probably not bear fruit during their political life-time. The Framework Convention for Tobacco Control (http://www.who.int/fctc/about/en/index.html) offers a good starting point. Long-term reductions in tobacco consumption have led to long-term declines in lung cancer incidence in a number of countries. Where we do know the cause(s) of cancer, the latency between causative exposure(s) and clinical disease is often measured in decades, not years, and for around half of all cancers, we do not know the cause, so primary prevention is not yet possible. Thus, even if every cancer prevention measure that we know to be effective today were applied to every person, worldwide, tomorrow, and even if those measures were instantly and completely effective, in every person overnight – for example, abolishing the 20-fold lung cancer risk in heavy smokers – millions of people would continue to be diagnosed with cancer each and every year for the foreseeable future. Unfortunately, cancer prevention is not even close to being that prompt, that effective, or that widespread: the Framework Convention for Tobacco Control was adopted by the World Health Assembly in 2003, more than 50 years after the discovery that tobacco smoking causes cancer. The millions of cancer patients diagnosed every year will continue to need ready access to optimal treatment to optimize their chances of survival, wherever they live. The provision of adequate health care is a responsibility for governments everywhere. The survival of all cancer patients diagnosed with cancer in a given population is one of the most important measures we have of the overall effectiveness of the health care system for the treatment and management of cancer. Unsurprisingly, there is huge global inequity in access to cancer care2. The first CONCORD study showed for the first time that global disparities in cancer survival were equally wide3. CONCORD-2 will bring those estimates up to date. It will initiate global surveillance of cancer survival (Figure 1). Variation in survival  Much of the global variation in survival is likely to be attributable to differences in access to diagnostic and treatment services, and lack of investment in health resources3. This is also true for children: about 80% of childhood cancers arise in low-income countries, where low survival is associated with failure either to start treatment, or to complete it, in up to 60% of cases4. Variation in survival within Europe is associated with national wealth (gross domestic product), total national expenditure on health and the level of investment in health technology such as CT scanners5,6. International differences in survival can be viewed through the same lens as the differences in survival within a given country between rich and poor7,8 or insured and under-insured9 patients. Survival also varies widely between countries of low- and middle-income10. The priorities for improving outcomes differ between these economic groups of countries11. Cancer control plans Inequalities in cancer survival revealed by the EUROCARE studies12-14 are partly responsible for the re-appearance of cancer control on the political agenda of the European Union15-17. Survival trends have also provided an instructive backdrop for the evaluation of cancer control strategies in Europe and the USA18. Today, some national cancer plans are explicitly focused on improving survival. Within the last 15 years, also, international disparities in survival have underpinned cancer plans in Denmark (2005)19, Northern Ireland (1996)20, England (2000, 2007)21,22, Wales (2006)23, Victoria (Australia) (2008)24 and Sweden (2009)25. Cancer survival trends are now also being used to evaluate the effectiveness of national cancer plans once they have been implemented, by assessing their contribution to improving overall survival26,27 or reducing socioeconomic inequalities in survival28. Global surveillance of cancer survival Population-based cancer survival provides one measure of progress in cancer control. It is important to evaluate patterns and trends in incidence and mortality alongside those for survival29. Comparisons of incidence, survival and mortality have been published for many cancers in Europe30,31, and for Europe, Australia and Canada32, but not worldwide. Where possible, incidence, survival and mortality trends will be compared for countries participating in CONCORD-2, to help improve the interpretation of survival comparisons29,30,32,33. Reliable information on global trends and disparities in cancer patient survival can be expected to help focus debate on reducing geographic and racial or ethnic inequalities11. Long-term surveillance of worldwide trends in cancer incidence has provided information for aetiological research and the basis of prevention and screening since the 1960s34,35. We can predict that continuous, global surveillance of cancer survival will become equally valuable: a reliable information source for cancer patients and researchers, a stimulus for change in health policy and health care systems, and a key metric for the global surveillance of cancer control. Global surveillance of cancer survival is seen as important by many national and international agencies (Figure 2). At the World Cancer Congress in Geneva in 2008, the Union for International Cancer Control (UICC) updated the World Cancer Declaration36,37, with 11 ambitious goals to be achieved by 2020, including: “there will be major improvements in cancer survival rates… in all countries”. UICC is committed to providing progress reports every two years. The CONCORD programme for surveillance of cancer survival supports several of the goals in the UICC World Cancer Declaration (Figure 3). The Organisation for Economic Co-operation and Development (www.oecd.org), Paris, endorses the CONCORD programme, which will provide cancer survival information for 30 of its 34 Member States (Figure 4).

Figure 1: Aims of the CONCORD-2 study

To provide quantitative and directly comparable estimates of cancer survival in many countries world-wide, for 10 malignancies that are common in adults, and childhood leukaemia, using individual data from population-based cancer registries, supplied to agreed standards and analysed centrally. To document world-wide trends in cancer survival since 1995 as the basis for systematic global surveillance of cancer survival, to enable examination of the underlying causes of survival differences, and to derive measures such as the population “cure” fraction, cancer prevalence and the number of avoidable premature deaths as a basis for informing national and global policy for cancer control.

Figure 2: The CONCORD programme is endorsed by

• WHO Regional Office for Europe (WHO-EURO) (Copenhagen) • Organisation for Economic Co-operation and Development (OECD) (Paris) • Canadian Association of Provincial Cancer Agencies (CAPCA) (Toronto) • Jolanta Kwaśniewska Foundation (Warsaw) • Members of the European Parliament Against Cancer (MAC) (Brussels) • Association of European Cancer Leagues (ECL) (Brussels) • Danish Cancer Society (Copenhagen) • European CanCer Organisation (ECCO) (Brussels) • Asociación Española contra el Cáncer (aecc) (Madrid) • North American Association of Central Cancer Registries (NAACCR) (Chicago) • US National Cancer Institute, Center for Global Health (Washington DC) • Many other bodies (list on request)
CONCORD-2 study: Global trends in cancer survival since 1995 CONCORD was the first world-wide study to provide direct comparisons of cancer survival between high-income and low-income countries, using standard quality control criteria and the same analytic method for all data sets3. It provided estimates of five-year survival for 1.9 million adults (aged 15–99 years) diagnosed during 1990–94 and followed up to 1999. Individual tumour records were supplied by 101 population-based cancer registries in 31 countries on five continents. Sixteen of the 31 countries provided data with national coverage. Global variation was wide: 5-year relative survival for breast (women), colorectal and prostate cancers was generally higher in North America, Australia and Japan, and in northern, western and southern Europe, and lower or much lower in Algeria, Brazil, and eastern Europe. CONCORD-2 will quantify international differences and trends in survival since 1995 in 50 or more countries on all five continents. It will include 10 common malignancies: cancers of the stomach, colon, rectum, liver, lung, breast (women), ovary, cervix and prostate in adults (15-99 years), and leukaemia in adults and children (0-14 years). These 10 cancers represent 63% of all new cancer cases and deaths, both in developed and developing38 regions of the world (Table 1). The proportions for individual cancers differ widely between rich and poor countries: whereas prostate cancer comprises 22% of new cases among men in high-income countries, the proportion is only 7% in low- and middle-income countries, while liver cancer comprises 9% of cancers in LMIC but only 2% in high-income countries. Of 350 population-based cancer registries invited to participate, over 220 registries in 60 countries have registered their intent to contribute data. Participation from low- and middle-income countries is expected to include 26 of these countries: 8 in Africa, 8 in Central and South America, 7 of the 13 Asian countries and 3 of the 24 in Europe. About half the countries will contribute national data (100% population coverage). Most registries have indicated they will provide data for patients diagnosed during all or part of the period 1995-2009. The end of follow-up will be 31 December 2009, or a later year if adequate data are available from most registries. Data from more recent years of diagnosis and follow-up will be accepted as the programme develops. By 2013, CONCORD-2 will start to provide regular information on world-wide cancer survival trends.

Figure 3: CONCORD programme fits UICC World Cancer Declaration goals

• To provide information on world-wide survival trends since the 1990s (goal 11). • To help measure the cancer burden and the impact of cancer control interventions (goal 2). • To help dispel myths about the inevitability of death from cancer (goal 5). • To provide training opportunities for cancer professionals (goal 9). … and UICC high-priority health policies: • to bridge gaps in worldwide cancer surveillance. • to increase the number of health professionals with expertise in cancer control.

Figure 4: Organisation of Economic Co-operation and Development (OECD) endorses CONCORD

“ … [the first CONCORD study] has contributed to a sea-change in how national policy makers are using international comparisons to improve their health systems”. “… [OECD considers the] proposals for a CONCORD-2 study, with its objective of producing data on cancer survival trends up to 2009 for 10 major cancers, to be extremely important. We are excited by the prospect of being able to use your data to address the contribution of health system characteristics in explaining international differences in cancer survival. This is one of the tasks which our Member countries have given us for the next few years.”
Inequalities in survival and avoidable premature deaths Equal treatment for a given cancer should yield equal outcome, regardless of race39, geography or socio-economic status40. Racial, ethnic and socio-economic differences in survival can reflect differences in access to optimal health services for population groups within a country41,42. The wider public health impact of cancer survival disparities can also contribute to the formulation of health strategy43, and these aspects will be examined in the CONCORD programme where data are available. Thus, estimates of avoidable premature cancer deaths in Britain since the mid-1990s, derived from the persistent UK survival deficit identified in the EUROCARE studies44, have become central to the initiative for earlier diagnosis in the UK45 International, regional and socio-economic disparities in survival represent large numbers of avoidable premature deaths44,46. Even in the Nordic countries, where survival is high, some 5,300 (2.5%) of the deaths from 12 common cancers during 2008–2012 would have been avoidable by elimination of regional variations in survival43. In Europe more widely, disparities in five-year survival between the Nordic countries and other European countries may have represented up to 150,000 avoidable premature deaths a year during 1995–99, or 12% of the 1.3 million cancer deaths a year that happen within five years of diagnosis47. Estimation of the number of avoidable premature deaths among cancer patients in a wider range of populations will contribute to the UICC World Cancer Declaration (goal #2) of improving measurement of the cancer burden, and of the impact of cancer control interventions36. The proportion of patients who are “cured” Identifying individual cancer patients who may be considered clinically cured is problematic. However, the proportion of all cancer patients who may be considered “cured” can still be estimated from the point when a curve of relative (or net) survival reaches a plateau. This indicates that, as a group, the cancer patients who have survived up to that time after diagnosis no longer have significant excess mortality over that of the general population48-50. Estimates of “cure” have been made for patients with cancers of the bowel, breast and cervix in Europe51. Similar approaches will be used to estimate the proportion of patients who may be considered cured, and the mean survival time of patients who die before the point of cure is reached. It may be possible to estimate “cure” for cancers of the bowel and cervix, and for childhood leukaemia52, but probably not for breast53, lung or liver cancers. “Cure” estimates are not affected by lead-time bias.   Training and capacity development The statistical methodology for cancer survival is undergoing rapid development. The CONCORD programme contains a commitment to training analysts in cancer survival techniques. The training programme is designed to help improve the capacity of cancer registries to undertake survival analyses independently. The Cancer Survival Group at the London School of Hygiene has run annual courses since 2006. Over 300 students from 40 countries have attended these courses, and a further 350 or so have attended our courses and advanced workshops in seven other countries in the last few years. The capacity-building component of the CONCORD programme is growing, and we are seeking training fellowships to support cancer registry scientists from low- and middle-income countries.   Global spotlight on noncommunicable disease The United National General Assembly High-Level Meeting in New York in September 2011 set new strategic objectives for worldwide control of noncommunicable diseases54. The UN resolution emphasized the need for wider research into global prevention and control of all noncommunicable diseases, including cancer, because of their rapidly growing impact on public health in developing countries in particular. At a preparatory conference in Russia in April 2011, Dr Margaret Chan, WHO Director-General, said: “Without global goals or targets, this is not going to fly – what gets measured gets done.” Global inequalities in cancer survival are wide, and potentially avoidable. Unless they are measured, and reported regularly, nothing will be done to ameliorate them. Global surveillance of cancer survival will shine a new light on the effectiveness of national health systems in managing the world’s growing cancer burden. Surveillance will highlight international differences, national trends and racial/ethnic inequalities in cancer survival. The information will stimulate cancer patients, the wider public and politicians to seek improvement.
Professor Michel P Coleman qualified in medicine in Oxford last century and practised in internal medicine and general practice before deserting to epidemiology. He worked in the Cancer Epidemiology Unit in Oxford (1984–87), at WHO’s International Agency for Research on Cancer in Lyon (1987–1991), and as Medical Director of the Thames Cancer Registry in London (1991–95). He has been Professor of Epidemiology and Vital Statistics at the London School of Hygiene & Tropical Medicine since 1995. His research has focused on time trends and socioeconomic inequalities in cancer incidence, mortality and survival, and their application to improve public health policy for cancer control.


1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 http://dx.doi.org/10.3322/caac.20107
2. International Atomic Energy Agency. Inequity in cancer care: a global perspective. IAEA Human Health Reports No. 3 . Vienna, IAEA, 2011.
3. Coleman MP, Quaresma M, Berrino F, Lutz J-M, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, Micheli A, Sant M, Weir HK, Elwood JM, Tsukuma H, Koifman S, Azevedo e Silva G, Francisci S, Santaquilani M, Verdecchia A, Storm HH, Young JL, CONCORD Working Group. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008; 9: 730-56
4. Mostert S, Arora RS, Arreola M, Bagai P, Friedrich P, Gupta S, Kaur G, Koodiyedath B, Kulkarni K, Lam CG, Luna-Fineman S, Pizer B, Rivas S, Rossell N, Sitaresmi MN, Tsimicalis A, Weaver M, Ribeiro RC. Abandonment of treatment for childhood cancer: position statement of a SIOP PODC Working Group. Lancet Oncol 2011 PM:21719348
5. Micheli A, Coebergh JWW, Mugno E, Massimiliani E, Sant M, Oberaigner W, Holub J, Storm HH, Forman D, Quinn MJ, Aareleid T, Sankila R, Hakulinen T, Faivre J, Ziegler H, Tryggvadóttir L, Zanetti R, Dalmas M, Visser O, Langmark F, Bielska-Lasota M, Wronkowski Z, Pinheiro PS, Brewster DH, Pleško I, Pompe-Kirn V, Martinez-Garcia C, Barlow L, Moller T, Lutz J-M, Andre M, Steward JA. European health systems and cancer care. Ann Oncol 2003; 14 (Suppl. 5): 41-61
6. Vercelli M, Lillini R, Capocaccia R, Micheli A, Coebergh JWW, Quinn M, Martinez-Garcia C, Quaglia A. Cancer survival in the elderly: effects of socio-economic factors and health care system features (ELDCARE project). Eur J Cancer 2006; 42: 234-42 PM:16359860
7. Kogevinas M, Porta M. Socioeconomic differences in cancer survival: a review of the evidence. In: Kogevinas M, Pearce N, Susser M, Boffetta P, eds. Social inequalities and cancer. (IARC Scientific Publications No. 138). Lyon: International Agency for Research on Cancer; 1997, pp177-206.
8. Woods LM, Rachet B, Coleman MP. Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol 2006; 17: 5-19 doi:10.1093/annonc/mdj007
9. McDavid K, Tucker T, Sloggett A, Coleman MP. Cancer survival in Kentucky and health insurance coverage. Arch Intern Med 2003; 163: 2135-44
10. Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, Law SCK, Ahn YO, Xiang YB, Yeole BB, Shin HR, Shanta V, Woo ZH, Martin N, Sumitsawan Y, Sriplung H, Barboza AO, Eser S, Nene BM, Suwanrungruang K, Jayalekshmi P, Dikshit R, Wabinga H, Esteban DB, Laudico A, Bhurgri Y, Bah E, Al-Hamdan N. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol 2010;
11: 165-73 PM:20005175 11. Anderson BO, Cazap E, El Saghir NS, Yip CH, Khaled HM, Otero IV, Adebamowo CA, Badwe RA, Harford JB. Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. Lancet Oncol 2011; 12: 387-98 http://linkinghub.elsevier.com/retrieve/pii/S1470204511700316
12. Berrino F, Capocaccia R, Coleman MP, Estève J, Gatta G, Hakulinen T, Micheli A, Sant M, Verdecchia A, eds. Survival of cancer patients diagnosed in Europe: the EUROCARE-3 study. Ann Oncol 2003; 14 (Suppl. 5): pp1-155
13. Berrino F, De Angelis R, Sant M, Rosso S, Lasota MB, Coebergh JWW, Santaquilani M, EUROCARE Working Group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 773-83
14. Capocaccia R, Gavin A, Hakulinen T, Lutz J-M, Sant M, eds. Survival of cancer patients diagnosed in Europe, 1995-2002: the EUROCARE-4 study. Eur J Cancer 2009; 45 (Suppl. 6): pp901-1094
15. Commission of the European Communities. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Action against Cancer: European Partnership. Commission of the European Communities 24 Jun 2009. http://ec.europa.eu/health/ph_information/dissemination/diseases/docs/com_2009_291.en.pdf, last accessed 24 June 2009. 16. Coleman MP, Alexe DM, Albreht T, McKee CM, eds. Responding to the challenge of cancer in Europe. Ljubljana: Institute of Public Health of the Republic of Slovenia; 2008, pp1-327
17. Council of the European Union. Council conclusions on reducing the burden of cancer. 2876th Employment, social policy, health and consumer affairs council meeting. Luxembourg, Council of the European Union, 10 June 2008.
18. Trubek LG, Oliver TR, Liang C-M, Mokrohisky M, Campbell T. Improving cancer outcomes through strong networks and regulatory frameworks: lessons from the United States and the European Union. J Health Care Law Pol 2011; 14: 119-51
19. National Board of Health. National Cancer Plan II – Denmark. Copenhagen, Denmark, National Board of Health, 1 June 2005.
20. Cancer Working Group. Cancer Services – Investing for the Future (The Campbell Report). Belfast, Department of Health and Social Services, 1996.
21. Department of Health. The NHS Cancer Plan. London, Department of Health, 2000.
22. Department of Health. Cancer Reform Strategy. London, Department of Health, June 2007.
23. Cancer Services Co-ordinating Group. Designed to Tackle Cancer in Wales: A Welsh Assembly Government Policy Statement. Welsh Assembly Government, December 2006. http://www.wales.nhs.uk/sites3/Documents/322/D2TC_Strategic_ Framework_2008-11.pdf
24. Department of Human Services. Victoria’s Cancer Action Plan 2008-2011. Melbourne, Victoria, Victorian Government Department of Human Services, 2008. 25. Commission of Inquiry on a National Cancer Strategy. A national cancer strategy for the future. Swedish Government Official Reports SOU 2009:11. Stockholm, Sweden, Swedish Government Inquiries, 2009. http://www.regeringen.se/content/1/c6/12/09/76/01389b21.pdf
26. Rachet B, Maringe C, Nur U, Quaresma M, Shah A, Woods LM, Ellis L, Walters S, Forman D, Steward JA, Coleman MP. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol 2009; 10: 351-69
27. Storm HH, Gislum M, Engholm G. [Cancer survival before and after initiating the Danish Cancer Control plan] [In Danish, English abstract]. Ugeskr Læger [Danish Medical Journal] 2008; 170: 3065-9 PM:18822235 28. Rachet B, Ellis L, Maringe C, Nur U, Chu T, Quaresma M, Shah A, Walters S, Woods LM, Forman D, Coleman MP. Socioeconomic inequalities in cancer survival in England after the NHS Cancer Plan. Br J Cancer 2010; 103: 446-53
29. Extramural Committee to Assess Measures of Progress Against Cancer. Measurement of progress against cancer. J Natl Cancer Inst 1990; 82: 825-35
30. Karim Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JWW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008; 44: 1345-89 PM:18280139
31. Sant M, Francisci S, Capocaccia R, Verdecchia A, Allemani C, Berrino F. Time trends of breast cancer survival in Europe in relation to incidence and mortality. Int J Cancer 2006; 119: 2417-22
32. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA, ICBP Module 1 Working Group. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011; 377: 127-38 http://linkinghub.elsevier.com/retrieve/pii/S0140673610622313
33. Coleman MP, Babb P, Stockton DL, Møller H, Forman D. Trends in breast cancer incidence, survival and mortality [Erratum in Lancet 2000;356:774]. Lancet 2000; 356: 590-1 34. Doll R, Payne P, Waterhouse JAH, eds. Cancer incidence in five continents: a technical report. Geneva: UICC; 1966
35. Ferlay J, Parkin DM, Curado MP, Bray F, Edwards BK, Shin HR, Forman D. Cancer incidence in five continents, volumes I to IX: IARC CancerBase No. 9 [Internet]. Available from: http://ci5.iarc.fr. IARC 2010. http://ci5.iarc.fr, last accessed 28 July 2011.
36. Union for International Cancer Control. World Cancer Declaration. UICC 2010. http://www.uicc.org/declaration/world-cancer-declaration, last accessed 28 July 2011.
37. Cavalli F. The World Cancer Declaration: a roadmap for change. Lancet Oncol 2008; 9: 810-1 PM:18760235 38. World Bank. List of economies (18 July 2011). World Bank, Washington DC 2011. http://data.worldbank.org/about/country-classifications/country-and-lending-groups, last accessed 3 August 2011.
39. Brawley OW, Freeman HP. Race and outcomes: is this the end of the beginning for minority health research? J Natl Cancer Inst 1999; 91: 1908-9
40. Rachet B, Woods LM, Mitry E, Riga M, Cooper C, Quinn MJ, Steward JA, Brenner H, Estève J, Sullivan R, Coleman MP. Cancer survival in England and Wales at the end of the 20th century. Br J Cancer 2008; 99 (Suppl. 1): 2-10
41. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. J Amer Med Assoc 2002; 287: 2106-13
42. Brawley OW. Disaggregating the effects of race and poverty on breast cancer outcomes. J Natl Cancer Inst 2002; 94: 471-3 http://jnci.oxfordjournals.org
43. Dickman PW, Gibberd RW, Hakulinen T. Estimating potential savings in cancer deaths by eliminating regional and social class variation in cancer survival in the Nordic countries. J Epidemiol Comm Hlth 1997; 51: 289-98
44. Abdel-Rahman MA, Stockton DL, Rachet B, Hakulinen T, Coleman MP. What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable? Br J Cancer 2009; 101 (Suppl. 2): 115-24
45. Richards MA. The size of the prize for earlier diagnosis of cancer in England. Br J Cancer 2009; 101 (Suppl. 2): 125-9 http://dx.doi.org/10.1038/sj.bjc.6605402
46. Pokhrel A, Martikainen P, Pukkala E, Rautalahti M, Seppä K, Hakulinen T. Education, survival and avoidable deaths in cancer patients in Finland. Br J Cancer 2010; 103: 1009-114
47. Berrino F, Capocaccia R. Survival of European cancer patients. In: Coleman MP, Alexe DM, Albreht T, McKee CM, eds. Responding to the challenge of cancer in Europe. Ljubljana: Institute of Public Health of the Republic of Slovenia; 2008, pp151-76.
48. Hawkins MM. Long term survival and cure after childhood cancer. Arch Dis Child 1989; 64: 798-807
49. Verdecchia A, De Angelis R, Capocaccia R, Sant M, Micheli A, Gatta G, Berrino F. The cure for colon cancer: results from the EUROCARE study. Int J Cancer 1998; 77: 322-9 Cherie1990Sposto R. Cure models analysis in cancer: an application to data from the Children’s Cancer Group. Stat Med 2002; 21: 293-312 51. Francisci S, Capocaccia R, Grande E, Santaquilani M, Simonetti A, Allemani C, Gatta G, Sant M, Zigon G, Bray F, Janssen-Heijnen MLG, EUROCARE-4 Working Group. The cure of cancer: a European perspective. Eur J Cancer 2009; 45 (Suppl. 6): 1067-79 52. Shah A, Stiller CA, Kenward M, Vincent T, Eden TO, Coleman MP. Childhood leukaemia: long-term excess mortality and the proportion ‘cured’. Br J Cancer 2008; 99: 219-23 53. Woods LM, Rachet B, Lambert PC, Coleman MP. ‘Cure’ from breast cancer among two populations of women followed for 23 years after diagnosis. Ann Oncol 2009; 20: 1331-6 54. Partridge EE, Mayer-Davis EJ, Sacco RL, Balch AJ. Creating a 21st century global health agenda: The General Assembly of the United Nations High Level Meeting on Non-Communicable Diseases. CA Cancer J Clin 2011; 61: 209-11 PM:21593443